0000000000076815

AUTHOR

Giovanni Cardinale

showing 3 related works from this author

Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules

2009

Splenectomy and splenic irradiation (SI) are the sole treatment modalities to control drug resistant splenomegaly in patients with myelofibrosis (MF). SI has been used in poor surgical candidates but optimal total dose and fractionation are unclear. We retrospectively reviewed 14 MF patients with symptomatic splenomegaly. Patients received a median of 10 fractions in two weeks. Fraction size ranged from 0.2–1.4 Gy, and total dose varied from 2–10.8 Gy per RT course. Overall results indicate that 81.8% of radiation courses achieved a significant spleen reduction. Splenic pain relief and gastrointestinal symptoms reduction were obtained in 94% and 91% of courses, respectively. Severe cytopeni…

medicine.medical_specialtypalliationmedicine.medical_treatmentSplenectomyMyelofibrosisSpleenSubgroup analysisGastroenterologyArticleInternal medicineMedicinemyelofibrosis; splenomegaly; palliation; radiotherapy; low-dose irradiationMyelofibrosisAdverse effectradiotherapylow dose irradiationsplenomegalylcsh:RC633-647.5business.industrylow-dose irradiation.lcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTolerabilityToxicitybusinessHematology Reports
researchProduct

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A R…

2019

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years

Oncologymedicine.medical_specialtySalvage therapylcsh:MedicineContext (language use)Article03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinesalvage therapyKRd regimen; multiple myeloma; salvage therapyMultiple myelomaLenalidomideCumulative dosebusiness.industrylcsh:RGeneral Medicinemedicine.diseaseCarfilzomibKRd regimenClinical trialmultiple myelomaTolerabilitychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual…

2015

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

OncologyCD20Prognostic variablemedicine.medical_specialtyPathologyHistologybiologybusiness.industryCD58Cell BiologyPlasma cellmedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureImmunophenotypingInternal medicinemedicinebiology.proteinStage (cooking)businessCytometryMultiple myelomaCytometry Part B: Clinical Cytometry
researchProduct